SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-16-018509
Filing Date
2016-08-04
Accepted
2016-08-04 16:14:36
Documents
55
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20160630x10q.htm 10-Q 734077
2 EXHIBIT 10.21 mrtx63016ex1021.htm EX-10.21 64140
3 EXHIBIT 31.1 mrtx63016ex311.htm EX-31.1 12454
4 EXHIBIT 31.2 mrtx63016ex312.htm EX-31.2 13386
5 EXHIBIT 32.1 mrtx63016ex321.htm EX-32.1 8357
12 g160621ko01i001.jpg GRAPHIC 3606
13 g160621ko01i002.jpg GRAPHIC 937
  Complete submission text file 0001628280-16-018509.txt   3203461

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT mrtx-20160630.xml EX-101.INS 656361
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20160630.xsd EX-101.SCH 23024
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20160630_cal.xml EX-101.CAL 44670
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20160630_def.xml EX-101.DEF 61957
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20160630_lab.xml EX-101.LAB 271364
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20160630_pre.xml EX-101.PRE 147617
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 161807594
SIC: 2834 Pharmaceutical Preparations